Enhancing glycoprotein sialylation by targeted gene silencing in mammalian cells
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Recombinant glycoproteins produced by mammalian cells represent an important category of therapeutic pharmaceuticals used in human health care. Of the numerous sugars moieties found in glycoproteins, the terminal sialic acid is considered particularly important. Sialic acid has been found to influence the solubility, thermal stability, resistance to protease attack, antigenicity, and specific activity of various glycoproteins. In mammalian cells, it is often desirable to maximize the final sialic acid content of a glycoprotein to ensure its quality and consistency as an effective pharmaceutical. In this study, CHO cells overexpressing recombinant human interferon gamma (hIFNγ) were treated using short interfering RNA (siRNA) and short‐hairpin RNA (shRNA) to reduce expression of two newly identified sialidase genes, Neu1 and Neu3. By knocking down expression of Neu3 we achieved a 98% reduction in sialidase function in CHO cells. The recombinant hIFNγ was examined for sialic acid content that was found to be increased 33% and 26% respectively with samples from cell stationary phase and death phase as compared to control. Here, we demonstrate an effective targeted gene silencing strategy to enhance protein sialylation using RNA interference (RNAi) technology. Biotechnol. Bioeng. 2010;105: 1094–1105. © 2009 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intracellular Functions of N-Linked Glycans
Helenius, A., & Aebi, A. M. (2001) · Science · doi:10.1126/science.291.5512.2364 · Cited by 2,405 · cited 2×
“In recombinant therapeutic glycoprotein production, the lack of sialic acid exposes other sugars to degradation by attack with different glycosidases and introduces a lot of glycoform heterogeneity and inconsistency of glycosylated therapeutic proteins (Helenius and Aebi, 2001).”
BackgroundCarbohydrate-Specific Receptors of the Liver
Ashwell, G., & Harford, J. (1982) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.51.070182.002531 · Cited by 1,914
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
An improved zinc-finger nuclease architecture for highly specific genome editing
Miller, J. C., Holmes, M. C., Wang, J., Guschin, D. Y., Lee, Y.-L., Rupniewski, I., Beausejour, C. M., Waite, A. J., Wang, N. S., Kim, K. A., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1319 · Cited by 1,051 · cited 2×
“…to examine protein sialylation enhancement by permanently knocking out these sialidase genes from the CHO genome with Zinc-Finger Nuclease (ZFN) based gene-targeting strategy (Miller et al., 2007; Santiago et al., 2008), to provide another effective way to further maximize protein sialylation.”
BackgroundRecapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc
Anthony, R. M., Nimmerjahn, F., Ashline, D. J., Reinhold, V. N., Paulson, J. C., & Ravetch, J. V. (2008) · Science · doi:10.1126/science.1154315 · Cited by 849 · cited 1×
“Maximizing sialyation of mAb provides an effective strategy to enhance mAb anti-inflammatory activity against autoimmune disease (e.g., rheumatoid arthritis) (Anthony et al., 2008).”
BackgroundHinek, A., Pshezhetsky, A. V., von Itzstein, M., & Starcher, B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508736200 · Cited by 176 · cited 2×
“These sialidases have been found to be very crucial to many biophysiological processes, such as cell differentiation regulation, tumorigenesis, neuronal differentiation and genetic defects (Fanzani et al., 2004; Geest et al., 2002; Hinek et al., 2006; Kakugawa et al., 2002; Papini et al., 2004; Seyrantepe et al., 2004…”
Backgroundde Geest, N. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.12.1455 · Cited by 127 · cited 2×
“These sialidases have been found to be very crucial to many biophysiological processes, such as cell differentiation regulation, tumorigenesis, neuronal differentiation and genetic defects (Fanzani et al., 2004; Geest et al., 2002; Hinek et al., 2006; Kakugawa et al., 2002; Papini et al., 2004; Seyrantepe et al., 2004…”
BackgroundRNA interference of sialidase improves glycoprotein sialic acid content consistency
Ngantung, F. A., Miller, P. G., Brushett, F. R., Tang, G. L., & Wang, D. I. C. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20997 · Cited by 97 · cited 6×
“It has been reported that, when cytosolic sialidase (Neu2) in CHO cells was knocked down by RNAi, sialic acid content of glycoprotein expressed from the targeted cells was improved (Ferrari et al., 1998; Ngantung et al., 2006).”
BackgroundResultInfluential
Cited by
The art of CHO cell engineering: A comprehensive retrospect and future perspectives
Fischer, S., Handrick, R., & Otte, K. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.10.015 · Cited by 312
Therapeutic glycoprotein production in mammalian cells
Lalonde, M.-E., & Durocher, Y. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.04.028 · Cited by 296
“Some attempts of knocking down the different CHO sialidases by shRNA or siRNA also improved the sialylation level of recombinant hIFNγ, particularly for Neu2 and Neu3 sialidases (Ngantung et al., 2006; Zhang et al., 2010b).”
BackgroundInfluentialAntibody glycoengineering strategies in mammalian cells
Wang, Q., Chung, C., Chough, S., & Betenbaugh, M. J. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26567 · Cited by 95
Lin, N., Mascarenhas, J., Sealover, N. R., George, H. J., Brooks, J., Kayser, K. J., Gau, B., Yasa, I., Azadi, P., & Archer‐Hartmann, S. (2015) · Biotechnology Progress · doi:10.1002/btpr.2038 · Cited by 73
Self-citationGlycoengineering in CHO cells: advances in systems biology
Tejwani, V., Andersen, M. R., Nam, J. H., & Sharfstein, S. T. (2018) · Biotechnology Journal · doi:10.1002/biot.201700234 · Cited by 70
Wang, Z., Park, J. H., Park, H. H., Tan, W., & Park, T. H. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.23091 · Cited by 50
“Permanent knockdown of sialidase using short-hairpin RNA in CHO cells producing IFN-g reduced its expression by up to 98%, resulting in a 33% (stationary phase), and 26% (death phase) increase in the sialic acid content (Zhang et al., 2010).”
MethodAmann, T., Schmieder, V., Faustrup Kildegaard, H., Borth, N., & Andersen, M. R. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.27101 · Cited by 46
“IFN-ɣ CHO (DG44) siRNA/shRNA KD (NEU1, NEU3) Sialylation ↑ (Zhang et al., 2010)”
Glycoengineering Chinese hamster ovary cells: a short history
Donini, R., Haslam, S. M., & Kontoravdi, C. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200840 · Cited by 37
Goh, J. S. Y., Liu, Y., Liu, H., Chan, K. F., Wan, C., Teo, G., Zhou, X., Xie, F., Zhang, P., Zhang, Y., et al. (2014) · Biotechnology Journal · doi:10.1002/biot.201300301 · Cited by 22
“The knockdown of sialidase through RNA interference has also demonstrated an increase in sialic acid content of human interferon-gamma [12].”
Background
Metadata
- Authors
- Zhang, M., Koskie, K., Ross, J. S., Kayser, K. J., & Caple, M. V.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2010-01-19
- Volume
- 105
- Issue
- 6
- Pages
- 1094-1105
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2110568229
- Cited by
- 62
- References
- 8
- FWCI
- 0.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.